MannKind Corporation MNKD reported its fourth-quarter and full-year 2025 financial results on Friday. The company reported ...

As of Wednesday, February 25, MannKind Corporation’s MNKD share price has dipped by 13.18%, which has investors questioning ...

Q4 2025 revenues of $112M, +46% vs. Q4 2024Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 ...

MannKind (NASDAQ:MNKD) reported record fourth-quarter revenue and outlined key regulatory and clinical catalysts for 2026 ...

MannKind (MNKD) delivered earnings and revenue surprises of -900.00% and +15.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) stock plunges after Q4 2025 earnings miss despite 46% revenue growth driven mainly by Tyvaso DPI royalties. Read more here.

Shares of MannKind fell after the biopharmaceutical company posted an unexpected loss in the fourth quarter. The stock slid 9.3%, to $3.18, Thursday afternoon, at one point touching a 52-week low of ...

MannKind Corporation (NASDAQ:MNKD) shares fell 37% Wednesday after partner United Therapeutics unveiled a soft-mist inhaler that will compete with dry powder inha ...

MannKind (NASDAQ:MNKD) reaches a 1-year low, with its performance in Nasdaq Futures influencing broader biopharma market trends.

Q4 2025 Earnings Call February 26, 2026 9:00 AM ESTCompany ParticipantsMichael Castagna - CEO & DirectorChristopher ...